…
Benchmark Holdings plc, together with its subsidiaries, engages in the provision of technical services, products, and specialist knowledge that supports the development of food and farming industries. It operates through Genetics, Advanced Nutrition, and Health segments. The Genetics segment offers sea bass and bream, salmon, and shrimp breeding technologies and production facilities to the harnesses industry to provide various genetic merit ova. The Advanced Nutrition segment manufactures and provides nutrition and health products to the aquaculture industry. The Health segment provides health products, including Ectosan Vet and CleanTreat medicinal sea lice solutions to the aquaculture market. The company operates in the United Kingdom, Norway, Vietnam, Iceland, the Faroe Islands, China, Ecuador, India, Canada, Greece, Chile, Turkey, rest of the Europe, and internationally. Benchmark Holdings plc was incorporated in 2000 and is headquartered in Sheffield, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | -12.69M | -23.18M | -9.18M | -22.57M | -73.30M |
| Minority interest | -1.58M | -1.64M | -1.31M | 6.31M | 6.14M |
| Net income | -23.15M | -30.45M | -11.58M | -22.77M | -73.29M |
| Selling general administrative | - | - | - | - | 0.21M |
| Gross profit | 86.75M | 83.13M | 65.58M | 54.96M | 66.00M |
| Reconciled depreciation | 37.21M | 39.06M | 24.64M | 28.54M | 83.31M |
| Ebit | -0.47M | -4.76M | -1.01M | -7.68M | -64.95M |
| Ebitda | 36.74M | 34.30M | 23.63M | 20.86M | 18.36M |
| Depreciation and amortization | 37.21M | 39.06M | 24.64M | 28.54M | 83.31M |
| Operating income | -5.32M | -4.76M | -1.01M | -7.68M | -64.95M |
| Other operating expenses | 170.86M | 165.56M | 129.35M | 114.47M | 187.60M |
| Interest expense | 10.50M | 11.42M | 7.99M | 12.78M | 6.09M |
| Tax provision | 3.37M | 7.27M | 2.40M | 0.20M | -0.01M |
| Interest income | 0.63M | 4.74M | 4.18M | 0.10M | 0.37M |
| Net interest income | -9.87M | -15.32M | -3.80M | -8.28M | -5.73M |
| Income tax expense | 3.37M | 7.27M | 2.40M | 0.20M | -0.01M |
| Total revenue | 169.48M | 158.28M | 125.06M | 105.56M | 127.34M |
| Total operating expenses | 88.13M | 90.41M | 69.87M | 63.87M | 126.25M |
| Cost of revenue | 82.73M | 75.15M | 59.48M | 50.60M | 61.35M |
| Total other income expense net | -7.38M | -18.42M | -8.17M | -14.89M | -8.35M |
| Discontinued operations | - | - | - | -9.17M | -23.96M |
| Net income from continuing ops | -16.06M | -30.45M | -11.58M | -22.77M | -73.29M |
| Net income applicable to common shares | - | -32.09M | -12.89M | -32.92M | -83.86M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 471.30M | 526.57M | 481.99M | 489.04M | 503.38M |
| Intangible assets | 103.59M | 130.54M | 130.34M | 145.76M | 167.16M |
| Other current assets | - | 56.38M | 46.50M | 39.37M | 16.02M |
| Total liab | 188.68M | 203.29M | 202.39M | 193.59M | 192.91M |
| Total stockholder equity | 276.40M | 313.40M | 271.71M | 289.13M | 304.33M |
| Deferred long term liab | - | 27.24M | 25.80M | 21.97M | 18.71M |
| Other current liab | 28.37M | 11.84M | 6.20M | 4.34M | 13.74M |
| Common stock | 0.74M | 0.70M | 0.67M | 0.67M | 0.56M |
| Capital stock | 0.74M | 0.70M | 0.67M | 0.67M | 0.56M |
| Retained earnings | 183.49M | -185.14M | -154.23M | -142.17M | -110.92M |
| Other liab | - | 36.99M | 29.14M | 34.40M | 40.75M |
| Good will | 102.49M | 114.72M | 98.70M | 101.25M | 108.58M |
| Other assets | - | 48.12M | 47.05M | 38.59M | 31.18M |
| Cash | 36.52M | 36.40M | 39.46M | 71.61M | 16.05M |
| Total current liabilities | 75.08M | 73.26M | 63.52M | 55.38M | 52.21M |
| Net debt | 65.47M | 73.74M | 80.93M | 37.55M | 87.14M |
| Short term debt | 20.05M | 17.09M | 10.65M | 5.34M | 3.23M |
| Short long term debt | 8.48M | 5.57M | 1.61M | 2.86M | 3.10M |
| Short long term debt total | 102.00M | 110.14M | 120.39M | 109.16M | 103.19M |
| Other stockholder equity | 92.18M | 497.83M | 425.28M | 430.63M | 414.69M |
| Property plant equipment | - | 108.93M | 104.31M | 75.95M | 88.90M |
| Total current assets | 150.03M | 148.37M | 124.03M | 145.75M | 122.79M |
| Long term investments | - | - | - | - | 3.48M |
| Net tangible assets | - | 95.37M | 68.48M | 64.09M | 47.29M |
| Net receivables | 24.85M | 40.50M | 34.36M | 28.43M | 52.08M |
| Long term debt | 73.66M | 78.28M | 94.79M | 95.86M | 99.50M |
| Inventory | 52.85M | 55.59M | 38.07M | 34.77M | 38.63M |
| Accounts payable | 26.66M | 44.32M | 46.67M | 45.69M | 35.23M |
| Accumulated other comprehensive income | - | - | - | - | -28.27M |
| Common stock total equity | - | - | - | 0.67M | 0.56M |
| Non currrent assets other | 21.98M | 24.01M | 24.61M | 20.33M | 15.95M |
| Non current assets total | 321.27M | 378.20M | 357.96M | 343.29M | 380.59M |
| Capital lease obligations | 19.86M | 26.29M | 23.99M | 10.44M | 0.59M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -5.27M | 1.17M | -0.57M | 6.41M | -1.08M |
| Change to liabilities | - | 6.95M | 5.55M | 5.01M | 3.97M |
| Total cashflows from investing activities | - | -11.22M | -23.09M | 30.38M | -15.32M |
| Net borrowings | - | -17.47M | -7.71M | -3.87M | 21.35M |
| Total cash from financing activities | -12.33M | -6.92M | -14.67M | 30.13M | 15.98M |
| Change to operating activities | - | 1.06M | -5.43M | -0.26M | 0.26M |
| Net income | -21.56M | -30.45M | -11.58M | -31.95M | -83.08M |
| Change in cash | 0.13M | -3.06M | -32.15M | 55.55M | -8.04M |
| Begin period cash flow | 36.40M | 39.46M | 71.61M | 16.05M | 24.09M |
| End period cash flow | 36.52M | 36.40M | 39.46M | 71.61M | 16.05M |
| Total cash from operating activities | 20.00M | 10.81M | 5.79M | -4.06M | -9.21M |
| Issuance of capital stock | 13.02M | 20.74M | 0.75M | 42.98M | 0.00M |
| Depreciation | 37.21M | 39.06M | 24.64M | 28.54M | 83.31M |
| Other cashflows from investing activities | - | 0.12M | 0.09M | 1.49M | 0.45M |
| Change to inventory | 1.22M | -11.51M | -8.98M | -3.73M | -10.87M |
| Change to account receivables | - | -8.51M | -8.18M | 4.20M | -12.52M |
| Other cashflows from financing activities | -6.88M | 47.22M | -12.31M | -2.70M | 87.21M |
| Change to netincome | - | 16.82M | 5.98M | 0.40M | 21.08M |
| Capital expenditures | 6.78M | 12.72M | 22.72M | 11.41M | 15.81M |
| Change in working capital | -1.06M | -12.01M | -11.61M | 5.21M | -19.15M |
| Stock based compensation | 1.00M | 1.18M | 0.83M | 1.67M | 1.18M |
| Other non cash items | 7.73M | 13.03M | 6.54M | 9.78M | 7.47M |
| Free cash flow | 13.22M | -1.91M | -16.93M | -15.47M | -25.02M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HLN Haleon PLC |
-4.20 1.10% |
376.00 | 20.24 | 18.94 | 2.95 | 2.02 | 3.68 | 14.19 |
| HIK Hikma Pharmaceuticals PLC |
4.00 0.24% |
1704.00 | 9.73 | 9.03 | 0.85 | 1.45 | 1.53 | 6.07 |
| HCM HUTCHMED China Ltd |
-2.00 0.95% |
208.00 | 5.38 | 19.30 | 3.37 | 2.02 | 2.25 | 2.40 |
| AGY Allergy Therapeutics |
- -% |
4.25 | - | 106.38 | 11.72 | 159.47 | 12.12 | -4.15 |
Benchmark Holdings plc, together with its subsidiaries, engages in the provision of technical services, products, and specialist knowledge that supports the development of food and farming industries. It operates through Genetics, Advanced Nutrition, and Health segments. The Genetics segment offers sea bass and bream, salmon, and shrimp breeding technologies and production facilities to the harnesses industry to provide various genetic merit ova. The Advanced Nutrition segment manufactures and provides nutrition and health products to the aquaculture industry. The Health segment provides health products, including Ectosan Vet and CleanTreat medicinal sea lice solutions to the aquaculture market. The company operates in the United Kingdom, Norway, Vietnam, Iceland, the Faroe Islands, China, Ecuador, India, Canada, Greece, Chile, Turkey, rest of the Europe, and internationally. Benchmark Holdings plc was incorporated in 2000 and is headquartered in Sheffield, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Trond Williksen | CEO & Director | 1963 |
| Ms. Septima Maguire | CFO & Director | NA |
| Ms. Ruth Layton | Co-Founder & Head of Benchmark Sustainability Science | NA |
| Mr. Neil Robertson | Head of Operations | NA |
| Ms. Ivonne Maria Gloria Cantu | Director of Investor Relations & Corp. Devel. and Head of Sustainability Working Group | 1969 |
| Ms. Jennifer Haddouk | Company Sec. & Group Legal Counsel | NA |
| Ms. Corina Holmes | Group Head of People | NA |
| Mr. Roland James Bonney | Group Lead of Key Account Management | 1964 |
| Mr. David Babington | Managing Director of Improve International | NA |
| Mr. John Marshall | Head of Health | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.